Abstract We investigated plasma phosphorylated tau217 (p-tau217) and p-tau181 efficacy in predicting positive amyloid positron emission tomography (PET) results and cognitive stage transitions. Plasma p-tau217 and p-tau181 were measured in participants who were cognitively unimpaired (CU, n = 121), had mild cognitive impairment (n = 102), or dementia (n = 75) from two independent cohorts (Cohort 1: KBASE-V and Cohort 2: Asan) who underwent amyloid PET.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jee Hyang
Angiotensin-converting enzyme insertion/deletion gene polymorphism and the progression of cerebral microbleeds
Introduction Cerebral small vessel disease (CSVD) is a disorder of the small perforating arterioles, capillaries, and venules of the brain (1). Clinically, CSVD is a major contributor to stroke (both ischemic and hemorrhagic) and dementia. CSVD causes about a quarter of ischemic strokes and most hemorrhagic strokes, is the most common cause of vascular dementia, and often co-occurs with Alzheimer’s disease (1).
Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study
Alzheimer's Research & Therapy, Aug 2023 Subjective cognitive decline (SCD) is a risk factor for Alzheimer’s disease (AD); however, the rates of cognitive decline are variable according to underlying pathologies and biomarker status. We conducted an observational study and aimed to investigate baseline characteristics and biomarkers related with cognitive declines in SCD.
Impact of a multidomain lifestyle intervention on white matter integrity: the SUPERBRAIN exploratory sub-study
1. Introduction Recent research suggests that multidomain lifestyle interventions, which encompass dietary counseling, physical exercise, cognitive training, and vascular/metabolic risk monitoring, can confer cognitive benefits to individuals at risk of developing cognitive decline.
Impacts of baseline biomarkers on cognitive trajectories in subjective cognitive decline: the CoSCo prospective cohort study - Alzheimer's Research & Therapy
Study design This study is part of a prospective longitudinal cohort study named “COhort study to identify predictors for the clinical progression to mild cognitive impairment or dementia from Subjective COgnitive decline (CoSCo).” Detailed study design is described in a previous report [9]. In brief, the CoSCo study was conducted in six centers in South Korea and enrolled SCD participants between November 2018 and December 2021.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jee
Contact Jee, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack